Gene expression profiling reveals 2 overarching types of ALCL with distinct targetable biology: an LLMPP study

亚型 基因表达谱 生物 计算生物学 癌症研究 间变性大细胞淋巴瘤 间变性淋巴瘤激酶 EZH2型 表观遗传学 仿形(计算机编程) 基因表达 基因 免疫组织化学 遗传异质性 生物信息学 医学 病理
作者
Andrew L. Feldman,Surendra Dasari,Lisa M. Rimsza,David W. Scott,Naoki Oishi,Guangzhen Hu,Pedro Farinha,Catalina Amador,Elı́as Campo,Wing C. Chan,James R. Cook,Jan Delabie,Kai Fu,Timothy C. Greiner,Laura K. Hilton,Giorgio Inghirami,Javeed Iqbal,Elaine S. Jaffe,Ryan D. Morin,Sarah L. Ondrejka
出处
期刊:Blood [Elsevier BV]
卷期号:147 (11): 1199-1214 被引量:3
标识
DOI:10.1182/blood.2024027700
摘要

ABSTRACT: Anaplastic large cell lymphomas (ALCLs) are CD30+ T-cell lymphomas that share pathologic features but differ in presentation, outcome, and genetics. Current classification incorporates clinical presentation and anaplastic lymphoma kinase (ALK) status but inadequately addresses molecular heterogeneity and therapeutic vulnerabilities. We studied 689 patients with ALCL in the LLMPP (Lymphoma/Leukemia Molecular Profiling Project) and performed expert consensus review, genetic subtyping (ALK, DUSP22, TP63, and triple negative), and immunohistochemistry for phosphorylated STAT3Tyr705. RNA sequencing with unsupervised gene expression profiling in 393 patients identified 2 main molecular types of ALCL that could be predicted with 91% accuracy based on the presence (type I) or absence (type II) of phosphorylated STAT3Y705 expression. Type I ALCLs included ALK+ ALCL and a subset of triple-negative ALCLs (TN-I); type II ALCLs included tumors with DUSP22 and/or TP63 rearrangements and the remaining triple-negative ALCLs (TN-II). Type I ALCLs were enriched for JAK-STAT3, whereas type II ALCLs were enriched for non-tyrosine kinase pathways, particularly epigenetic regulators such as EZH2. Immunohistochemistry showed overexpression of EZH2 and its trimethylated substrate H3K27. Prognosis in systemic ALCL was favorable for DUSP22-rearranged ALCL (5-year overall survival, 95%) and ALK+ ALCL (88%), intermediate for triple-negative ALCL (TN-I, 52% and TN-II, 37%), and poor for TP63-rearranged ALCL (0%). We introduce an integrated molecular classification that preserves currently diagnosed ALCL entities but identifies 4 molecularly distinct ALK- ALCL subtypes (DUSP22-rearranged, TP63-rearranged, TN-I, and TN-II). This classification can be easily implemented on paraffin tissue in routine practice or clinical trials, and stratifies ALCL into diagnostically, prognostically, biologically, and potentially therapeutically relevant subtypes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
2秒前
Maxine完成签到 ,获得积分10
2秒前
贾硕士发布了新的文献求助10
3秒前
3秒前
3秒前
长情平彤发布了新的文献求助10
3秒前
隐形曼青应助lzzzz采纳,获得10
6秒前
常宝怡发布了新的文献求助10
6秒前
还不睡觉就是完成签到,获得积分10
6秒前
英吉利25发布了新的文献求助10
6秒前
文静的又琴完成签到,获得积分10
6秒前
科研通AI6.4应助秦大帅采纳,获得50
7秒前
YyHyY完成签到,获得积分10
7秒前
研友_VZG7GZ应助yy采纳,获得10
7秒前
Wang_ZiMo发布了新的文献求助10
9秒前
长情平彤完成签到,获得积分10
9秒前
shiwo110完成签到,获得积分10
10秒前
13秒前
刘豆豆完成签到,获得积分10
15秒前
molihuakai应助幽默的烨华采纳,获得10
16秒前
JL发布了新的文献求助10
17秒前
合适的凡完成签到,获得积分10
21秒前
Hello应助魔幻的可乐采纳,获得10
23秒前
充电宝应助刘小勇采纳,获得10
25秒前
25秒前
26秒前
研友_VZG7GZ应助mojomars采纳,获得10
28秒前
30秒前
隐形曼青应助123采纳,获得30
30秒前
kktwo应助蔡宇滔采纳,获得10
31秒前
甜蜜宛亦完成签到,获得积分10
32秒前
LinkChen发布了新的文献求助10
32秒前
32秒前
若一发布了新的文献求助10
33秒前
34秒前
李健应助胖虎采纳,获得10
34秒前
思源应助dandan采纳,获得10
34秒前
35秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Reducing Compassion Fatigue, Secondary Traumatic Stress and Burnout 600
China Pluperfect I: Epistemology of Past and Outside in Chinese Art 520
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
Mammalian Synthetic Biology 500
Auslegungsgeschichte 500
Cosmos as Art Object: Studies in Plato's Timaeus and Other Dialogues 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7638098
求助须知:如何正确求助?哪些是违规求助? 9211411
关于积分的说明 19758652
捐赠科研通 7205015
什么是DOI,文献DOI怎么找? 3275778
关于科研通互助平台的介绍 2437385
邀请新用户注册赠送积分活动 2272954